Friday May 18 | Local Tech Wire
Stem cell technology from Aldagen showing more promise
When regenerative medicine firm Cytomedix acquired biotechnology company Aldagen , the stem cell-based stroke treatment in clinical trials was the centerpiece of the all stock deal.
Cytomedix: A Little-Known Biotech With Big, PDUFA-Type Decision Coming Up
A little known biotech stock, Cytomedix , has a critical medical reimbursement decision coming up shortly that is expected to bring a lot of interest into the stock.